S-1/A: Allurion Technologies Announces Offering of Common Stock and Warrants

Allurion Technologies plans to raise capital through an offering of common stock, pre-funded warrants, and common warrants.

Summary

• Allurion Technologies, Inc. is offering up to 1,918,158 shares of common stock, or pre-funded warrants in lieu thereof, along with common warrants to purchase up to 2,877,237 shares of common stock.
• Each share of common stock comes with one common warrant, exercisable for 1.5 shares of common stock at an exercise price to be determined.
• The common warrants will be immediately exercisable and expire five years from the date of issuance.
• Pre-funded warrants are offered as an alternative to common stock for purchasers who would otherwise exceed a 4.99% (or 9.99%) ownership threshold.
• Each pre-funded warrant is exercisable for one share of common stock at a nominal exercise price of $0.0001.
• The pre-funded warrants are immediately exercisable and do not have an expiration date.
• The offering is being conducted on a reasonable best efforts basis, with Roth Capital Partners, LLC acting as the exclusive placement agent.
• The offering is expected to close on or about January 31, 2025, unless terminated earlier.
• The offering will settle delivery versus payment (DVP)/receipt versus payment (RVP).
• The last reported sale price of Allurion's common stock on the NYSE on January 7, 2025 was $7.82.
• The actual offering price and exercise price for the common warrants will be determined at the time of pricing and may be at a discount to the current market price.

Sentiment

Score: 6

Explanation: The document is neutral in tone, providing factual information about the offering. While the offering itself is a positive step for the company, the lack of a guaranteed minimum raise and the potential for dilution temper the overall sentiment.

Positives

• The offering provides flexibility for investors with pre-funded warrants as an alternative to common stock.
• The common warrants are immediately exercisable, providing potential for immediate gains.
• The offering is being conducted on a reasonable best efforts basis, which may attract a wider range of investors.

Negatives

• The offering price and exercise price for the common warrants may be at a discount to the current market price.
• There is no guarantee that the offering will be fully subscribed.
• The pre-funded warrants and common warrants will not be listed on the NYSE or any other national securities exchange or nationally recognized trading system.

Risks

• The actual public offering amount, placement agent fees and proceeds to the Company, if any, are not presently determinable and may be substantially less than the total maximum offering amounts.
• The pre-funded warrants and common warrants will not be listed on the NYSE and are not expected to trade in any market.
• The market prices used throughout the prospectus may not be indicative of the actual public offering price of the shares of common stock and accompanying common warrants offered hereunder.
• The offering will terminate on January 31, 2025, unless (i) the closing occurs prior thereto or (ii) the Company decides to terminate the offering prior thereto (which it may do at any time in its discretion).
• The Company is an emerging growth company and a smaller reporting company under the federal securities laws and is subject to reduced public company reporting requirements.

Future Outlook

The Company plans to use the net proceeds from the offering for commercial sales, research and development, working capital, and other general corporate purposes.

Industry Context

This offering is taking place in the context of a broader market for weight loss solutions, where companies are seeking capital to fund research, development, and commercialization efforts.

Comparison to Industry Standards

• The offering structure, including the use of common stock, pre-funded warrants, and common warrants, is a common approach for companies seeking to raise capital in the current market.
• The use of a reasonable best efforts placement agent is a standard practice for offerings of this type.
• The terms of the warrants, including the exercise price and expiration date, are generally consistent with industry standards.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Investors may have the opportunity to purchase securities at a discount to the current market price.
• The Company may be able to fund its operations and growth plans with the proceeds from the offering.

Next Steps

• The Company will determine the final offering price and exercise price for the common warrants.
• The Company will enter into securities purchase agreements with investors who choose to participate in the offering.
• The Company will deliver the securities to the investors upon receipt of funds.
• The Company will use the net proceeds from the offering for commercial sales, research and development, working capital, and other general corporate purposes.

Key Dates

Keywords

common stock, warrants, pre-funded warrants, offering, capital raise, Roth Capital Partners, securities, placement agent, exercise price, Allurion Technologies